Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody-Reference-Cited by-同舟云学术

Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody

Published:2002-06-15 Issue:12 Volume:76 Page:6408-6412
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Parren Paul W. H. I.¹,Geisbert Tom W.²,Maruyama Toshiaki¹,Jahrling Peter B.²,Burton Dennis R.¹

Affiliation:

1. Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037

2. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702

Abstract

ABSTRACT A neutralizing human monoclonal antibody, KZ52, protects guinea pigs from lethal Ebola Zaire virus challenge. Administration before or up to 1 h after challenge resulted in dose-dependent protection by the antibody. Interestingly, some antibody-treated animals survived despite developing high-level viremia, suggesting that the mechanism of protection by KZ52 may extend beyond reduction of viremia by virus neutralization. KZ52 is a promising candidate for immunoprophylaxis of Ebola virus infection.

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.76.12.6408-6412.2002

Reference38 articles.

1. Anonymous. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. W. H. O. 56:271-293.

2. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, B. J. Bernacky, T. A. Rizvi, R. Schmidt, L. R. Hill, M. E. Keeling, Y. Lu, J. E. Wright, T. C. Chou, and R. M. Ruprecht. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 : 200-206.

3. Borisevich, I. V., V. V. Mikhailov, V. P. Krasnyanskii, V. N. Gradoboev, E. V. Lebedinskaia, N. V. Potryvaeva, and G. D. Timan'kova. 1995. Development and study of the properties of immunoglobulin against Ebola fever. Vopr. Virusol. 40 : 270-273.

4. Bowen, E. T. W., G. Lloyd, G. Platt, L. B. McArdell, P. A. Webb, and D. I. H. Simpson. 1978. Virological studies on a case of Ebola virus infection in man and in monkeys, p. 80-85. In S. R. Pattyn (ed.), Ebola virus haemorrhagic fever. Elsevier, Amsterdam, The Netherlands.

5. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1999. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179(Suppl. 1): S248-S258.

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp;Antiviral Research;2024-06

2. Management of Hemorrhagic Fever Viruses: Intervention of Natural and Synthetic Products;Mini-Reviews in Medicinal Chemistry;2023-08-09

3. Antiviral neutralizing antibodies: from in vitro to in vivo activity;Nature Reviews Immunology;2023-04-17

4. Targeting Ara h 2 with human‐derived monoclonal antibodies prevents peanut‐induced anaphylaxis in mice;Allergy;2023-02-07

5. A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health;Biomedicines;2022-08-22